Gilead Sciences and Arcus Biosciences said they’ve expanded their three-year-old collaboration. An equity stake in Arcus, board seat for Gilead’s commercial chief and a streamlined immuno-oncology ...
Vancouver, British Columbia--(Newsfile Corp. - January 29, 2026) - Arcus Development Group Inc. (TSXV: ADG) ("Arcus" or the "Company") announces that it has completed a $2 million non-brokered unit ...
Arcus Biosciences (NYSE:RCUS) shares jumped 16% in post-market trading Monday following news that partner Gilead Sciences (NASDAQ:GILD) has increased its stake in the company to 33% to help accelerate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results